Talanki Viswanath, MD
Nephrology · Livonia, MINPI 1083639942
Payments from drug & device makers
Across 296 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$810
- Amgen$733
- Boehringer Ingelheim$557
- AstraZeneca$534
- Pfizer$440
- Astellas Pharma US Inc$426
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,06995%
- Education$2945%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 53 | $810 |
| Amgen(2 entities) | 41 | $733 |
| Boehringer Ingelheim | 33 | $557 |
| AstraZeneca(2 entities) | 29 | $534 |
| Pfizer | 27 | $440 |
| Astellas Pharma US Inc | 9 | $426 |
| Amarin Pharma, Inc. | 20 | $362 |
| Bayer | 11 | $215 |
| GSK | 13 | $206 |
| Lilly USA, LLC | 8 | $123 |
| Johnson & Johnson | 5 | $120 |
| E.r. Squibb & Sons, L.L.C. | 7 | $91 |
| Exact Sciences | 5 | $91 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $89 |
| Sumitomo Pharma America, Inc. | 4 | $80 |
| Novartis | 4 | $74 |
| Sunovion Pharmaceuticals Inc. | 3 | $53 |
| Merck | 3 | $46 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Mallinckrodt Hospital Products Inc. | 2 | $32 |
| Apellis Pharmaceuticals, Inc. | 1 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $30 |
| Boston Scientific | 1 | $25 |
| Urovant Sciences Inc | 1 | $24 |
| Cormedix Inc. | 1 | $23 |
| Vifor Pharma, Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $18 |
| Aurinia Pharma U.S., Inc. | 1 | $16 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Baxter Healthcare | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$5,363 in reported general payments places this provider in the 75th percentile of 325 nephrology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 160 | $171,684 |
| EliquisApixaban | 90 | $131,328 |
| JanuviaSitagliptin Phosphate | 61 | $76,429 |
| FarxigaDapagliflozin Propanediol | 51 | $65,685 |
| OzempicSemaglutide | 33 | $47,188 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $36,485 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 46 | $32,080 |
| MounjaroTirzepatide | 22 | $28,795 |
| XareltoRivaroxaban | 30 | $27,204 |
| RybelsusSemaglutide | 16 | $22,726 |
| TrulicityDulaglutide | 11 | $21,231 |
| KerendiaFinerenone | 15 | $19,679 |
| MyrbetriqMirabegron | 15 | $16,996 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $13,185 |
| Metoprolol Succinate | 427 | $7,475 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $557 | $171,684160 claims |
| PfizerEliquis, Paxlovid | $440 | $135,420107 claims |
| MerckJanuvia | $46 | $76,42961 claims |
| Novo NordiskOzempic, Rybelsus | $810 | $69,91449 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $206 | $68,56570 claims |
| AstraZenecaFarxiga | $534 | $65,68551 claims |
| Lilly USA, LLCMounjaro, Trulicity | $123 | $50,02733 claims |
| Johnson & JohnsonXarelto | $120 | $27,20430 claims |
| BayerKerendia | $215 | $19,67915 claims |
| Astellas Pharma US IncMyrbetriq | $426 | $16,99615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 325 nephrology providers in Michigan.
Other nephrology in Livonia
- Crystal Gardner-MartinLivonia$140K
- Michael MisuracaLivonia$10K
- Matthias KretzlerAnn Arbor$7.8M
- Fahd Al-SaghirPontiac$3.9M
- Kiran SaraiyaWarren$3.1M
- Alexander YevzlinAnn Arbor$1.3M
- Christopher ProvenzanoShelby Township$1.2M
- Joel TopfRoseville$1.1M
- Jennifer OdrenSaint Clair Shores$620K
- Zeenat BhatAnn Arbor$592K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.